BAP1 Suppresses Disulfidptosis via SLC7A11 and NADPH Regulation

Study Background and Research Question

Malignant transformation and tumor progression are tightly linked to the evasion of regulated cell death. Among the growing list of regulated cell death (RCD) pathways, disulfidptosis has recently emerged as a distinct mechanism characterized by excessive intracellular disulfide bond accumulation, particularly under metabolic stress such as glucose deprivation. While previous work established that BRCA1-Associated Protein 1 (BAP1) is a tumor suppressor exerting effects through apoptosis and ferroptosis, it was not clear whether BAP1 could regulate additional, newly described cell death modalities. The study by Wang et al. (Oncogenesis, 2024) seeks to clarify whether BAP1 impacts disulfidptosis and to elucidate the molecular pathways underlying this interaction.

Key Innovation from the Reference Study

The reference study provides the first direct evidence that BAP1 can significantly suppress disulfidptosis by modulating SLC7A11 expression and maintaining intracellular NADPH levels. This finding extends BAP1's tumor suppressive repertoire beyond apoptosis and ferroptosis, linking it to the regulation of cellular redox state and cystine metabolism. The work highlights the complex interplay between gene regulation, metabolic flux, and cell death in cancer biology, and offers a new mechanistic framework for understanding how tumor suppressors can counteract emerging forms of RCD.

Methods and Experimental Design Insights

The authors employed a multifaceted methodological approach. First, isogenic cancer cell lines with varying BAP1 expression were subjected to glucose deprivation to induce disulfidptosis. Cell viability assays and the use of specific cell death inhibitors helped delineate the unique features of disulfidptosis versus other RCD pathways. Accumulation of disulfide bonds in cytoskeletal proteins was monitored with biochemical assays and microscopy.

Genetic and pharmacological manipulation of SLC7A11—the cystine/glutamate antiporter—was central to the study. Overexpression or knockout of SLC7A11, and treatment with erastin (an SLC7A11 inhibitor), allowed the team to parse how BAP1’s effects depended on cystine uptake. Intracellular NADP+/NADPH ratios were quantified under different experimental conditions to establish the redox context. Finally, transcriptomic correlations in clear cell renal cell carcinoma (KIRC) patient data were used to validate the molecular relationships observed in vitro.

Protocol Parameters

• Disulfidptosis induction: Glucose starvation for 12–48 hours in culture, with or without SLC7A11 manipulation, to model metabolic stress-induced cell death.
• BAP1 modulation: Use of stable knockdown or overexpression constructs to adjust BAP1 levels in target cell lines prior to assays.
• SLC7A11 perturbation: Overexpression or CRISPR/Cas9-mediated knockout in isogenic backgrounds; erastin applied at 5–10 μM for SLC7A11 inhibition.
• Redox state assessment: NADP+/NADPH quantification using colorimetric or fluorometric kits according to manufacturer recommendations.
• Validation in patient samples: Correlation analysis of BAP1, SLC7A11, and NADPH pathway gene expression in RNA-seq datasets from KIRC patient samples.

Core Findings and Why They Matter

The study provides several critical insights:

• BAP1 suppresses disulfidptosis: Cells with high BAP1 expression are protected from disulfidptosis triggered by glucose starvation, as shown by decreased cell death and lower disulfide bond accumulation (Wang et al., 2024).
• SLC7A11 is a pivotal mediator: Overexpression of SLC7A11 or supplementation with cystine negates BAP1’s protective effect, while SLC7A11 inhibition (genetic or with erastin) abrogates the impact of BAP1 status.
• NADPH homeostasis is essential: BAP1 expression correlates with lower NADP+/NADPH ratios, suggesting a link between BAP1-mediated gene regulation and cellular redox buffering. This is further supported by positive correlations between BAP1 and NADPH-related genes in patient tumor samples.
• Clinical relevance: The regulatory axis of BAP1–SLC7A11–NADPH may contribute to tumor cell resistance to disulfidptosis, which could have implications for therapeutic strategies targeting metabolic vulnerabilities in cancer.

These findings collectively expand the known mechanisms of tumor suppression and point to novel intervention points in cancer metabolism.

Comparison with Existing Internal Articles

Research on regulated cell death—including ferroptosis and podocyte injury—frequently employs specialized chemical tools to model and dissect mechanisms of injury and protection. For example, recent reviews highlight how the aminonucleoside moiety of puromycin is widely used for inducing podocyte injury and proteinuria in animal models, enabling the study of cytoskeletal and metabolic stress in renal cells. Furthermore, protocols described in workflow guides and benchmark studies demonstrate the centrality of redox balance and transporter function in podocyte injury models, paralleling the role of SLC7A11 in cystine uptake and cellular stress. While these internal articles primarily address nephrotoxic models, the reference study’s mechanistic insights into SLC7A11, NADPH, and cytoskeletal disulfide stress provide a valuable conceptual bridge between cancer cell death research and renal pathophysiology models.

Limitations and Transferability

While the study by Wang et al. establishes a foundational link between BAP1, SLC7A11, and disulfidptosis, several caveats warrant consideration. Most experiments were performed in vitro using cancer cell lines, and thus, the generalizability to in vivo tumor biology or other tissue types remains to be validated. The precise molecular mechanism by which BAP1 regulates NADPH levels is not fully delineated and requires further investigation. Additionally, while the transcriptomic correlations in KIRC are compelling, functional studies in animal models and patient-derived tissues will be needed to translate these findings to clinical contexts. The cross-domain relevance to nephrology research—particularly podocyte injury models—should be explored with caution, as the specific molecular mediators and injury contexts may differ.

Research Support Resources

For investigators aiming to model regulated cell death, transporter function, or redox imbalances in experimental systems, established tools such as Puromycin aminonucleoside (SKU A3740) are widely adopted for inducing proteinuria and podocyte injury. As the aminonucleoside moiety of puromycin, this compound enables precise glomerular lesion induction and supports studies of cytoskeletal disruption—concepts that overlap with the disulfidptosis mechanisms described in the reference study. Detailed application guidance and solubility data are available from APExBIO to assist in the design of nephrotoxic and cell death assays.